drugset / Trial / NCT07620496
CAN1012 in Pre-malignant Oral Dysplasia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this trial is to examine the safety of CAN1012 delivered by intralesional injection ahead of planned surgical resection.
Timeline
- Start
- 2026-07-01
- Primary completion
- 2031-07
- Completion
- 2033-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAN1012 | Unknown | — | Other |
Indications
No indication recorded.